Pulmonarytyrosinekinase inhibitors are medications used to treat progressive lung diseases such aspulmonary fibrosiswhich cause scarring and thickening of thelungsresulting in loss of lung function. Pulmonary tyrosine kinase inhibitors prevent scar tissue formation in the lungs by inhibiting the activity of...
Tyrosine Kinase Receptor Inhibitors: A New Target for Anticancer Drug Development. Journal of Pharma Sci Tech, 2012; 1(2): 36-45.Bari SB, Adhikari S, Surana SJ (2012) Tyrosine kinase receptor inhibitors: a new target for anticancer drug development. J Pharma Sci Tech 1:36-45...
In the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and haemato-oncology. Because this new class of drugs is extensively used, serious drug–drug interactions are an increasing risk. In this Review, we give a comprehensive overview of known or suspected drug–drug...
Tyrosine kinase inhibitors (TKIs) are indicated for the treatment of a variety of malignancies due to their ability to interfere with cell communication and growth. Interactions that affect TKI metabolism are discussed. Dasatinib (Sprycel), erlotinib (Tarceva), gefitinib (Iressa), imatinib (Gleevec),...
www.nature.com/scientificreports OPEN received: 15 July 2015 accepted: 04 November 2015 Published: 08 December 2015 Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP- Glucuronosyltransferases Nan Zhang3, Yong Liu4 & Hyunyoung Jeong1,2 Tyrosine kinase ...
Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved, revolutionized the treatment of chronic myelogenous leukaemia, and other TKIs with different spectra of kinase inhibition are used to treat renal cell carcinoma, non-small-cell lung cancer and colon cancer. Studies also ...
82-86 Patients with GISTs often have dramatic and durable responses to the kinase inhibitors imatinib and sunitinib (Table 2-1).76,87 The FLT3 receptor, a third member of the RTK class that includes PDGFR and KIT, is involved in the development of normal hematopoietic cells. It contains an...
Human epidermal growth factor receptor 3 (HER3) Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) Resistance Antibody Antibody-drug conjugate (ADC) Non-small cell lung cancer (NSCLC) Sorry, something went wrong. Please try again and make sure cookies are enabledCited...
Therapeutic Drug Monitoring ofTyrosine Kinase Inhibitors UsingDried Blood MicrosamplesNick Verougstraete 1,2 , Veronique Stove 2,3 , Alain G. Verstraete 2,3and Christophe P. Stove 1 *1 Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University,Ghent,...
Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study Hemanth Naick Banavath1*, Om Prakash Sharma2*, Muthuvel Suresh Kumar2 & R. Baskaran1 1Department of Biochemistry & Molecular biology, School of ...